UPDATE: Stifel Starts AveXis (AVXS) at Hold

November 14, 2016 7:33 AM EST
Get Alerts AVXS Hot Sheet
Price: $52.51 --0%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 43
Trade AVXS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
(Updated - November 14, 2016 9:08 AM EST)

Stifel initiated coverage on AveXis (NASDAQ: AVXS) with a Hold rating and a price target of $65.

Analyst Katherine Breedis said, "We believe AVXS has strong management as well as an exciting gene therapy asset, Ph.I AVXS-101, which has demonstrated very encouraging early results in the treatment of children afflicted with Spinal Muscular Atrophy (SMA) Type 1. SMA-1 is a rare neurological disorder owing to mutation of the SMN gene (aka, “floppy baby syndrome”, which affects about 240 infants/year who often die before reaching 24 months). Based on early data, we believe AVXS-101 could receive US approval and launch in the US in 2019E, with the potential to generate $530 million in revenues by 2025. However, we believe much of the upside is already reflected in AVXS’ current valuation with AVXS shares up 40% (vs. IBB +11%) following news regarding the potential Ph.I, single-arm pivotal study pathway to potential registration on November 1, 2016 (+237% since AVXS’ IPO 2/11/16 vs. IBB +15%). Further, we also see potential headline risk with the upcoming near-term potential approval of Biogen/Ionis’ Spinraza (nusinersen) for all SMA subtypes in est. 4Q16/1Q17."

For an analyst ratings summary and ratings history on AveXis click here. For more ratings news on AveXis click here.

Shares of AveXis closed at $67.35 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Stifel, S1, IPO

Add Your Comment